Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man

Rust, Christian; Sauter, G; Oswald, Monika; Büttner, J.; Kullak-Ublick, G.A.; Paumgartner, Gustav; Beuers, Ulrich

doi:10.1016/s0168-8278(98)80697-1

Cited by 14 publications

(15 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We obtained an average plasma C4 level of 12 ng/ml using human samples from five normal males. This level is in good agreement with previously published data where averages from 8 ng/ml to 19 ng/ml have been reported (21,27,28,31,32). Our data on the relative differences of the C4 levels in rats, mice, and humans in the current investigation are in agreement with previously published data on the enzymatic activity of C7␣OH in these species.…”

Section: Figsupporting

confidence: 93%

Monitoring hepatic cholesterol 7α-hydroxylase activity by assay of the stable bile acid intermediate 7α-hydroxy-4-cholesten-3-one in peripheral blood

Gälman

Arvidsson

Angelin

et al. 2003

Journal of Lipid Research

175

149

View full text Add to dashboard Cite

We describe an accurate method for monitoring the enzymatic activity of hepatic cholesterol 7 ␣ -hydroxylase (C7 ␣ OH; CYP7A1), the rate-limiting and major regulatory enzyme in the synthesis of bile acids. Assay of 7 ␣ -hydroxy-4-cholesten-3-one (C4), an intermediate in bile acid synthesis, revealed that the level of C4 in peripheral blood serum or plasma showed a strong correlation to the enzymatic activity of hepatic C7 ␣ OH, both at steady-state conditions ( r ‫؍‬ 0.929) as well as during the rapid changes that occur during the diurnal phases. This assay should be of value in clarifying the regulation of bile acid synthesis in vivo in laboratory animals and humans since it allows for the monitoring of hepatic C7 ␣ OH activity using peripheral blood samples.

show abstract

Section: Figsupporting

confidence: 93%

Monitoring hepatic cholesterol 7α-hydroxylase activity by assay of the stable bile acid intermediate 7α-hydroxy-4-cholesten-3-one in peripheral blood

Gälman

Arvidsson

Angelin

et al. 2003

Journal of Lipid Research

175

149

View full text Add to dashboard Cite

show abstract

“…Poor tolerance due to the taste of this agent can be a problem (which can sometimes be addressed by flavoring with fruit juice). When both agents are used UDCA and cholestyramine should be spaced a minimum of four hours apart to prevent binding and loss of efficacy [216].…”

Section: Pruritusmentioning

confidence: 99%

EASL Clinical Practice Guidelines: Management of cholestatic liver diseases

2009

Journal of Hepatology

1,483

529

View full text Add to dashboard Cite

“…When both agents are used, UDCA and cholestyramine should be spaced a minimum of 4 h apart to prevent binding and loss of efficacy [196]. Rifampicin has a strong evidence base [197,198].…”

Section: Treatment Of Symptoms and Complicationsmentioning

confidence: 99%

Primary biliary cirrhosis: A 2010 update

Poupon

2010

Journal of Hepatology

249

206

View full text Add to dashboard Cite

Primary biliary cirrhosis (PBC) is a chronic inflammatory autoimmune disease that mainly targets the cholangiocytes of the interlobular bile ducts in the liver. The condition primarily affects middle-aged women. Without treatment, PBC generally progresses to cirrhosis and eventually liver failure over a period of 10-20 years. PBC is a rare disease with prevalence of less than 1/2000. PBC is thought to result from a combination of multiple genetic factors and superimposed environmental triggers. The contribution of the genetic predisposition is evidenced by the familial clustering. Several risk factors, including exposure to infectious agents and chemical xenobiotics, have been suggested. Ursodeoxycholic acid (UDCA) is currently the only FDA-approved medical treatment for PBC. When administered at doses of 13-15 mg/kg/day, a majority of patients with PBC have a normal life expectancy without additional therapeutic measures. One out of three patients does not adequately respond to UDCA therapy and may need additional medical therapy and/or liver transplantation. This review summarises current knowledge on the epidemiology, ethiopathogenesis, clinical, and therapeutic aspects of PBC.

show abstract

Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man

Cited by 14 publications

References 14 publications

Monitoring hepatic cholesterol 7α-hydroxylase activity by assay of the stable bile acid intermediate 7α-hydroxy-4-cholesten-3-one in peripheral blood

Monitoring hepatic cholesterol 7α-hydroxylase activity by assay of the stable bile acid intermediate 7α-hydroxy-4-cholesten-3-one in peripheral blood

EASL Clinical Practice Guidelines: Management of cholestatic liver diseases

Primary biliary cirrhosis: A 2010 update

Contact Info

Product

Resources

About